SG11202010064QA - Nk cell engaging antibody fusion constructs - Google Patents
Nk cell engaging antibody fusion constructsInfo
- Publication number
- SG11202010064QA SG11202010064QA SG11202010064QA SG11202010064QA SG11202010064QA SG 11202010064Q A SG11202010064Q A SG 11202010064QA SG 11202010064Q A SG11202010064Q A SG 11202010064QA SG 11202010064Q A SG11202010064Q A SG 11202010064QA SG 11202010064Q A SG11202010064Q A SG 11202010064QA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody fusion
- fusion constructs
- cell engaging
- engaging antibody
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18167385 | 2018-04-13 | ||
| EP18167384 | 2018-04-13 | ||
| EP18190661 | 2018-08-24 | ||
| EP18190662 | 2018-08-24 | ||
| PCT/IB2019/053040 WO2019198051A2 (en) | 2018-04-13 | 2019-04-12 | Nk cell engaging antibody fusion constructs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010064QA true SG11202010064QA (en) | 2020-11-27 |
Family
ID=66625219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010064QA SG11202010064QA (en) | 2018-04-13 | 2019-04-12 | Nk cell engaging antibody fusion constructs |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11001633B2 (en) |
| EP (1) | EP3774914A2 (en) |
| JP (1) | JP2021521275A (en) |
| KR (1) | KR20200143436A (en) |
| CN (3) | CN112119097B (en) |
| AU (1) | AU2019252970A1 (en) |
| BR (1) | BR112020020828A2 (en) |
| CA (1) | CA3095373A1 (en) |
| CL (2) | CL2020002625A1 (en) |
| CO (1) | CO2020014167A2 (en) |
| CR (1) | CR20200549A (en) |
| IL (1) | IL277925A (en) |
| MA (1) | MA52227A (en) |
| MX (1) | MX2020010728A (en) |
| PE (1) | PE20201346A1 (en) |
| PH (1) | PH12020551664A1 (en) |
| RU (1) | RU2022105827A (en) |
| SG (1) | SG11202010064QA (en) |
| TW (1) | TW202012441A (en) |
| WO (1) | WO2019198051A2 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220396635A1 (en) * | 2019-09-25 | 2022-12-15 | Universität Stuttgart | Trivalent binding molecules |
| WO2021116277A1 (en) * | 2019-12-10 | 2021-06-17 | Institut Pasteur | New antibody blocking human fcgriiia and fcgriiib |
| CA3160927A1 (en) | 2019-12-27 | 2021-07-01 | Affimed Gmbh | Method for the production of bispecific fcyriii x cd30 antibody construct |
| CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
| CA3200974A1 (en) * | 2020-11-08 | 2022-05-12 | Seagen Inc. | Combination therapy |
| MX2023006573A (en) * | 2020-12-03 | 2023-06-19 | Amgen Inc | Immunoglobuline constructs with multiple binding domains. |
| JP2024516230A (en) | 2021-04-30 | 2024-04-12 | ジェネンテック， インコーポレイテッド | Therapeutic and diagnostic methods and compositions for cancer |
| WO2023006082A1 (en) * | 2021-07-30 | 2023-02-02 | 启愈生物技术(上海)有限公司 | Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereof |
| IL308154A (en) | 2021-07-30 | 2023-12-01 | Affimed Gmbh | Duplexbodies |
| CN113929785B (en) * | 2021-09-10 | 2023-05-23 | 钦元再生医学(珠海)有限公司 | Chimeric antigen receptor immune cell capable of automatically secreting PD1-TREM2 bispecific antibody and application thereof |
| CA3233085A1 (en) * | 2021-09-24 | 2023-03-30 | Synergy Imt, Inc. | Composition of recombinant antigen binding molecules and method of making and using thereof |
| CA3233696A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
| WO2023079493A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
| CN116284385A (en) * | 2021-12-07 | 2023-06-23 | 信达细胞制药(苏州)有限公司 | P329G antibody targeting BCMA and combination and application of P329G antibody and chimeric antigen receptor cell |
| CN114349869B (en) * | 2021-12-20 | 2023-09-26 | 上海恩凯细胞技术有限公司 | Bispecific NK cell agonist, preparation method and application |
| WO2024027828A1 (en) * | 2022-08-05 | 2024-02-08 | Chimagen Biosciences, Ltd | Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20030012783A1 (en) | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| PL2406284T3 (en) | 2009-03-10 | 2017-09-29 | Biogen Ma Inc. | Anti-bcma antibodies |
| ES2582001T3 (en) * | 2010-02-25 | 2016-09-08 | Affimed Gmbh | Molecule that binds to antigen and uses thereof |
| RS64791B1 (en) | 2011-05-27 | 2023-11-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) - binding proteins |
| TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
| EP2825557B1 (en) | 2012-03-16 | 2017-06-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Soluble engineered monomeric fc |
| JP6514103B2 (en) * | 2012-07-06 | 2019-05-15 | ゲンマブ ビー．ブイ． | Dimer protein with triple mutation |
| ES2937015T3 (en) | 2012-11-01 | 2023-03-23 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Antibody against CD269 (BCMA) |
| ES2829499T3 (en) | 2013-02-05 | 2021-06-01 | Engmab Sarl | Method for the selection of antibodies against BCMA |
| KR20150130349A (en) * | 2013-03-15 | 2015-11-23 | 메르크 파텐트 게엠베하 | Tetravalent bispecific antibodies |
| AR095374A1 (en) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | UNION MOLECULES FOR BCMA AND CD3 |
| MX2016009050A (en) * | 2014-01-15 | 2016-12-09 | Zymeworks Inc | Bi-specific cd3 and cd19 antigen-binding constructs. |
| CA3138083A1 (en) * | 2014-12-22 | 2016-06-30 | Systimmune, Inc. | Bispecific tetravalent antibodies and methods of making and using thereof |
| WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| CA3219372A1 (en) * | 2015-05-04 | 2016-11-10 | Affimed Gmbh | Combination of a cd30xcd16 antibody with a pd-1 antagonist for therapy |
| EP3091031A1 (en) * | 2015-05-04 | 2016-11-09 | Affimed GmbH | Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor |
| EP3313881A1 (en) * | 2015-06-23 | 2018-05-02 | Innate Pharma | Multispecific nk engager proteins |
| ES2814550T3 (en) * | 2015-08-17 | 2021-03-29 | Janssen Pharmaceutica Nv | Anti-BCMA antibodies, bispecific antigen-binding molecules that bind BCMA and CD3, and uses thereof |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| CN105367660B (en) * | 2015-12-22 | 2018-12-21 | 深圳市北科生物科技有限公司 | A kind of bispecific antibody of anti-CD16A antigen and anti-MUC1 antigen |
| CN106632681B (en) * | 2016-10-11 | 2017-11-14 | 北京东方百泰生物科技有限公司 | Anti- EGFR and AntiCD3 McAb bispecific antibody and its application |
| EP3589655B1 (en) * | 2017-02-28 | 2022-10-26 | Affimed GmbH | Tandem-diabody for cd16a-directed nk-cell engagement |
-
2019
- 2019-04-12 SG SG11202010064QA patent/SG11202010064QA/en unknown
- 2019-04-12 JP JP2021504593A patent/JP2021521275A/en active Pending
- 2019-04-12 BR BR112020020828-0A patent/BR112020020828A2/en unknown
- 2019-04-12 MA MA052227A patent/MA52227A/en unknown
- 2019-04-12 AU AU2019252970A patent/AU2019252970A1/en active Pending
- 2019-04-12 WO PCT/IB2019/053040 patent/WO2019198051A2/en active Application Filing
- 2019-04-12 KR KR1020207032435A patent/KR20200143436A/en unknown
- 2019-04-12 PE PE2020001584A patent/PE20201346A1/en unknown
- 2019-04-12 RU RU2022105827A patent/RU2022105827A/en unknown
- 2019-04-12 EP EP19725409.7A patent/EP3774914A2/en active Pending
- 2019-04-12 CN CN201980033176.8A patent/CN112119097B/en active Active
- 2019-04-12 CN CN202111125475.XA patent/CN113817066A/en active Pending
- 2019-04-12 CA CA3095373A patent/CA3095373A1/en active Pending
- 2019-04-12 MX MX2020010728A patent/MX2020010728A/en unknown
- 2019-04-12 CR CR20200549A patent/CR20200549A/en unknown
- 2019-04-12 CN CN202111125559.3A patent/CN113880952A/en active Pending
- 2019-04-15 TW TW108113068A patent/TW202012441A/en unknown
- 2019-12-13 US US16/714,396 patent/US11001633B2/en active Active
-
2020
- 2020-10-08 PH PH12020551664A patent/PH12020551664A1/en unknown
- 2020-10-09 CL CL2020002625A patent/CL2020002625A1/en unknown
- 2020-10-11 IL IL277925A patent/IL277925A/en unknown
- 2020-11-12 CO CONC2020/0014167A patent/CO2020014167A2/en unknown
-
2021
- 2021-04-20 US US17/235,854 patent/US20210253698A1/en active Pending
-
2023
- 2023-04-14 CL CL2023001085A patent/CL2023001085A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112119097B (en) | 2021-10-15 |
| CN112119097A (en) | 2020-12-22 |
| RU2022105827A (en) | 2022-04-05 |
| US11001633B2 (en) | 2021-05-11 |
| US20200109202A1 (en) | 2020-04-09 |
| JP2021521275A (en) | 2021-08-26 |
| MA52227A (en) | 2021-04-21 |
| CN113817066A (en) | 2021-12-21 |
| AU2019252970A1 (en) | 2020-11-26 |
| CR20200549A (en) | 2021-03-18 |
| CA3095373A1 (en) | 2019-10-17 |
| WO2019198051A3 (en) | 2019-11-14 |
| KR20200143436A (en) | 2020-12-23 |
| PE20201346A1 (en) | 2020-11-25 |
| BR112020020828A2 (en) | 2021-01-19 |
| EP3774914A2 (en) | 2021-02-17 |
| CN113880952A (en) | 2022-01-04 |
| TW202012441A (en) | 2020-04-01 |
| US20210253698A1 (en) | 2021-08-19 |
| MX2020010728A (en) | 2020-11-06 |
| IL277925A (en) | 2020-11-30 |
| CL2023001085A1 (en) | 2023-10-06 |
| PH12020551664A1 (en) | 2021-12-13 |
| CO2020014167A2 (en) | 2021-04-08 |
| WO2019198051A2 (en) | 2019-10-17 |
| CL2020002625A1 (en) | 2021-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277925A (en) | Nk cell engaging antibody fusion constructs | |
| HK1257748A1 (en) | Bispecific t cell engaging antibody constructs | |
| HK1257749A1 (en) | Psma and cd3 bispecific t cell engaging antibody constructs | |
| EP3440191A4 (en) | Chimeric antigen receptor t cell compositions | |
| IL277414A (en) | Chimeric antigen receptor-modified nk-92 cells | |
| EP3274366B8 (en) | Chimeric antigen receptor | |
| EP3256492A4 (en) | Bi-specific chimeric antigen receptor and uses thereof | |
| EP3256496A4 (en) | Chimeric antigen receptors | |
| EP3528851A4 (en) | Cereblon-based heterodimerizable chimeric antigen receptors | |
| EP3568406A4 (en) | T cells expressing a chimeric antigen receptor | |
| IL278061A (en) | Anti-ror antibody constructs | |
| ZA202005837B (en) | Cd83-binding chimeric antigen receptors | |
| GB201820554D0 (en) | BTLA antibodies | |
| EP3604344A4 (en) | Chimeric antigen receptor | |
| IL279399A (en) | Multi-specific antibody constructs | |
| EP3752197A4 (en) | Nkg2d chimeric antigen receptors | |
| IL281428A (en) | Chimeric antigen receptor | |
| EP3635099A4 (en) | T cells expressing a chimeric antigen receptor | |
| SG11202001011XA (en) | Chimeric antigen receptor and car-t cells that bind cxcr5 | |
| EP3585403A4 (en) | Tim3-binding chimeric antigen receptors | |
| EP3567101A4 (en) | Natural killer cell expressing anti-cotinine chimeric antigen receptor | |
| GB201807862D0 (en) | Chimeric antigen receptor | |
| IL278992A (en) | Chimeric antigen receptor t cell therapy | |
| AU2016902764A0 (en) | Chimeric antigen receptor modified T cells | |
| IL283568A (en) | Anti-b7-h4 chimeric antigen receptor-modified nk-92 cells |